A new antiretroviral drug is set to make HIV treatment compliance easier for patients. The antiretroviral which has a chemical component known as Dolutegravir was unveiled on the second day of the 21st International Aids Conference in Durban.
The drug manufactured by Aspen Pharmacare Holdings is used in much smaller quantities than conventional antiretrovirals.
Aspen’s Spokesperson Stavros Nicolaou says the drug, which was launched two months ago, is used on its own with a combination of two other ARVs.
“The compound is used in much smaller quantities than your conventional antiretroviral, has a better safety profile and offers a number of advantages to existing treatment.”
Nicolaou says going forward the company aims to combine the ARVs into a single pill.